Summit Partners Public Asset Management, LLC
-0.65%
3か月リターン
$49.460
-0.846 (-1.71%)終値時点
Heartflow, Inc. is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). Its novel Heartflow Platform uses AI and advanced computational fluid dynamics to create a personalized 3D model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Heartflow RoadMap Analysis, Heartflow FFRCT Analysis, Heartflow Plaque Analysis and Heartflow PCI Navigator. Its Heartflow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. Heartflow RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review. Heartflow FFRCT Analysis calculates blood flow and pinpoints clinically significant CAD.
HeartFlow Inc is a good buy right now due to its current price of $49.74, a significant year-to-date change of +71.69%, and a gross margin that has improved to 83% in Q2 2026. The main risk is the negative net income, which stands at -24.57% for the latest quarter, indicating ongoing losses.

HeartFlow CEO Sells Shares for $1.8 Million Amid Strong Market Performance

HeartFlow CFO Sells Shares Worth $1.7 Million Amid Stock Surge

HeartFlow CFO Sells Shares Worth $1.7 Million

Heartflow Clinical Trial Significantly Reduces Invasive Heart Procedures

Heartflow FUSION Trial Significantly Reduces Invasive Heart Procedures
Heartflow, Inc. is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). Its novel Heartflow Platform uses AI and advanced computational fluid dynamics to create a personalized 3D model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Heartflow RoadMap Analysis, Heartflow FFRCT Analysis, Heartflow Plaque Analysis and Heartflow PCI Navigator. Its Heartflow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. Heartflow RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review. Heartflow FFRCT Analysis calculates blood flow and pinpoints clinically significant CAD. It operates in the Healthcare sector.
HeartFlow Inc is a good buy right now due to its current price of $49.74, a significant year-to-date change of +71.69%, and a gross margin that has improved to 83% in Q2 2026. The main risk is the negative net income, which stands at -24.57% for the latest quarter, indicating ongoing losses.
投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。